What should a single-page monitoring and follow‑up form include for a pediatric patient receiving growth hormone therapy (e.g., for idiopathic short stature, Turner syndrome, growth hormone deficiency, or chronic renal disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Growth Hormone Therapy Monitoring Form for Pediatric Patients

Schedule clinic visits every 3–6 months (more frequently for young children and those with advanced CKD) to systematically monitor treatment response and detect adverse effects 1.


PATIENT INFORMATION

  • Name: _________________ MRN: _________ DOB: _________
  • Diagnosis: ☐ GH Deficiency ☐ Idiopathic Short Stature ☐ Turner Syndrome ☐ SGA ☐ CKD ☐ Other: _______
  • GH Dose: _____ mg/kg/day Start Date: _________ Current Weight: _____ kg

ANTHROPOMETRIC MEASUREMENTS (Every Visit)

Date Height (cm) Height SDS Weight (kg) BMI BMI SDS Height Velocity (cm/yr)

Target: Height velocity increase >2 cm/year over baseline in first year 1
Mid-Parental Height: _____ cm ± _____ cm


PUBERTAL DEVELOPMENT (Annually for children >10 years)

Date Tanner Stage Notes

LABORATORY MONITORING

Every 3–6 Months:

  • IGF-1 Level: _____ ng/mL (Reference: _____) Date: _____
    • Maintain at 0 SDS for GHD; +1 to +2 SDS for non-GHD indications 2
  • Thyroid Function (TSH, Free T4): TSH _____ Free T4 _____ Date: _____
  • Glucose/HbA1c: _____ Date: _____ (Monitor closely in obese patients)
  • Calcium: _____ Phosphate: _____ Bicarbonate: _____ Date: _____

CKD Patients Only (Every 3 Months for Stage 3-4):

  • PTH Level: _____ pg/mL Date: _____ (Hold GH if PTH >500 pg/mL) 1
  • eGFR: _____ mL/min/1.73m² Date: _____ (Stop if unexplained decrease)

BONE AGE ASSESSMENT (Annually)

Date Chronological Age Bone Age (Left Wrist X-ray) BA/CA Ratio Interpretation

Action: Discontinue if accelerated bone maturation evident 1


ADHERENCE ASSESSMENT

  • Injection Technique Reviewed: ☐ Yes ☐ No
  • Missed Doses (past month): _____
  • Injection Site Rotation: ☐ Adequate ☐ Needs Education
  • Patient/Family Concerns: _________________________________

ADVERSE EFFECTS SCREENING (Every Visit)

Check if present and document:

  • ☐ Headaches/Visual Changes (Intracranial hypertension - STOP GH immediately) 1
  • ☐ Hip/Knee Pain (Obtain X-ray to rule out slipped capital femoral epiphysis - STOP if confirmed) 1
  • ☐ Symptoms of Hyperglycemia (Check glucose/HbA1c)
  • ☐ Injection Site Reactions/Lipoatrophy
  • ☐ Edema

TREATMENT RESPONSE EVALUATION

First Year Assessment:

Height velocity increase from baseline: _____ cm/year

  • If <2 cm/year improvement: 1
    1. Verify adherence (check IGF-1 level)
    2. Confirm weight-adjusted dosing
    3. Reassess nutritional/metabolic factors
    4. Consider discontinuation if no response after 6 months

Ongoing Assessment:

  • Height SDS Change: _____ (Goal: normalize adult height)
  • Approaching Genetic Target Height: ☐ Yes ☐ No
  • Growth Velocity <2 cm/year in late puberty: ☐ Yes ☐ No

CRITERIA FOR DISCONTINUATION 1

STOP GH immediately if:

  • ☐ Epiphyseal closure on X-ray
  • ☐ Renal transplantation performed
  • ☐ PTH >500 pg/mL (CKD patients - may restart when controlled)
  • ☐ Intracranial hypertension
  • ☐ Slipped capital femoral epiphysis
  • ☐ Unexplained eGFR decrease
  • ☐ Accelerated bone maturation
  • ☐ No response despite optimal control for 6+ months

Consider discontinuation if:

  • ☐ Genetic target height percentile reached
  • ☐ Growth velocity <2 cm/year with closed/closing growth plates

NEXT VISIT PLAN

Date: _________ Interval: ☐ 3 months ☐ 6 months
Labs Needed: ☐ IGF-1 ☐ Thyroid ☐ Glucose ☐ Metabolic Panel ☐ PTH (CKD)
Imaging: ☐ Bone Age ☐ Other: _______

Provider Signature: _________________ Date: _________

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.